| Ytd | -19.59% | |
| 1y | -15.65% |
| Open | 7.19 | Prev Close | 6.97 | Low | 7.06 | High | 7.20 | Mkt Cap | 28.58M |
| Vol | 11.76K | Avg Vol | 17.92K | EPS | -12.34 | P/E | -0.57 | Forward P/E | N/A |
| Beta | 1.02 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 7.06 | 200-d Avg | 7.85 | 1yr Est | 0.00 |
KYNB News
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings b
Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both
Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, S
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additiona
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estim
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial r
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targe
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings b
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasd
Kyntra Bio Inc. (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday's premarket session
SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasda
SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it i
FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Tha
FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimat
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third q
SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the